Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "USP"

397 News Found

Granules India received ANDA approval for Sildenafil for oral suspension
Drug Approval | December 06, 2023

Granules India received ANDA approval for Sildenafil for oral suspension

The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million


Eugia Pharma receives USFDA approval for Budesonide Inhalation Suspension
Drug Approval | December 01, 2023

Eugia Pharma receives USFDA approval for Budesonide Inhalation Suspension

The product is expected to be launched in FY25


Kesin Pharma announces FDA approval and availability of Likmez oral suspension
Drug Approval | November 15, 2023

Kesin Pharma announces FDA approval and availability of Likmez oral suspension

Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing


GeoVax secures multi-product license for ProBioGen's AGE1.CR.pIX suspension cell line
Drug Approval | September 27, 2023

GeoVax secures multi-product license for ProBioGen's AGE1.CR.pIX suspension cell line

The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types


Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%
Drug Approval | September 21, 2023

Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Clindamycin Phosphate Gel is used to treat acne


Strides receives USFDA approval for Sevelamer Carbonate for oral suspension
Drug Approval | September 11, 2023

Strides receives USFDA approval for Sevelamer Carbonate for oral suspension

The products will be manufactured at the company's facility in Bengaluru


Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension
Drug Approval | August 31, 2023

Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension

The approval bolsters the company's Mycophenolate Mofetil portfolio


Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP
Drug Approval | August 16, 2023

Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP

Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).


Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
Drug Approval | August 06, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023


Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP
Drug Approval | July 14, 2023

Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP

Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.